Nurix Therapeutics has received a $10 million research term extension fee after Gilead Sciences agreed to extend the research term for an undisclosed oncology program by two years.

This marks the second two-year extension for this specific program within the companies' ongoing strategic collaboration. The agreement, originally established in 2019, leverages Nurix's proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets.

Collaboration terms and financial potential

Under the amended agreement, Nurix retains options for 50/50 profit and loss sharing for development and commercialization on up to two programs in the United States. For these selected programs, the parties will share U.S. development costs, profits, and losses equally. Nurix will also be eligible to receive royalties on ex-U.S. sales and reduced milestone payments.

As of May 31, 2026, Nurix is eligible to receive up to approximately $1.3 billion in total payments based on additional fees and the successful completion of preclinical, clinical, development, and sales milestones. The company is also entitled to mid-single-digit to low-teens percentage tiered royalties on annual net sales from any commercial products.

Platform capabilities and clinical progress

Gwenn M. Hansen, chief scientific officer of Nurix, stated that the extension reflects Gilead’s commitment to productive collaborations and the potential of Nurix’s targeted protein degradation platform. The collaboration has already advanced GS-6791, an oral IRAK4 degrader discovered by Nurix, into Phase 1 clinical development.

"This extension provides further evidence of the value of the collaboration and the capabilities of our platform," Hansen said. The partnership aims to discover and advance additional drug candidates across oncology and inflammatory diseases.

What the numbers show

The receipt of a $10 million upfront fee for a two-year extension indicates strong partner confidence in the pipeline's viability. When viewed against the total potential milestone value of $1.3 billion, this initial payment represents less than 1% of the maximum deal value, highlighting that the majority of Nurix's financial upside remains contingent on future clinical and commercial successes rather than immediate cash inflows.

Nurix Therapeutics (NASDAQ: NRIX) announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer. This payment targets the discovery and development of degrader antibody conjugates (DACs), an emerging therapeutic modality.

The milestone brings the total amount received by Nurix under this agreement to $82 million. The collaboration, originally entered into with Seagen Inc. (now part of Pfizer) in September 2023, includes an upfront payment of $60 million and potential future milestones totaling up to $3.4 billion.

Collaboration financial structure

The deal provides Nurix with significant non-dilutive funding through upfronts and milestones, alongside long-term royalty streams. The table below outlines the key financial components disclosed:

Strategic significance of DACs

Degrader antibody conjugates combine the cell selectivity of antibodies with the catalytic mechanism of targeted protein degraders. Unlike traditional antibody-drug conjugates (ADCs) that deliver cytotoxic payloads, DACs deliver targeted protein degraders to eliminate specific disease-driving proteins. This approach offers multiple layers of selectivity based on cell-surface antigen expression and E3 ligase activity.

Pipeline context

Nurix focuses on targeted protein degradation medicines for cancer and autoimmune diseases. Its clinical-stage oncology pipeline includes bexobrutideg, co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). The company also maintains collaborations with Gilead Sciences and Sanofi for other clinical-stage candidates.

What the numbers show

The $7 million milestone represents approximately 11.6% of the total $82 million received to date, indicating that the majority of cash inflows remain tied to the initial upfront rather than ongoing research achievements. With potential milestones capped at $3.4 billion, the current received amount constitutes roughly 2.4% of the maximum theoretical value, highlighting the early stage of value realization in this partnership.